Egalet Corp (EGLT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Egalet Corp (EGLT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10106
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Egalet Corp (Egalet) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for pain and other conditions. Its product portfolio includes OXAYDO (oxycodone HCl, USP) tablets CII for the management of acute and chronic moderate to severe pain; SPRIX (ketorolac tromethamine) nasal spray for short-term management of moderate to moderately severe pain; and and Arymo ER (morphine sulfate) extended-release tablets C-II for chronic pain. The company develops products based on its proprietary Guardian technology, a polymer matrix tablet technology. Egalet is also developing pipeline of products using its Guardian Technology. It operates research facility, pilot manufacturing and administrative facility in Denmark. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp (EGLT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Egalet Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Egalet Corp, Medical Devices Deals, 2012 to YTD 2018 10
Egalet Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Egalet Corp, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Egalet to Acquire Four Non-Narcotic Pain Products from Iroko Pharma 12
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 14
Venture Financing 16
Egalet Raises USD15 Million in Venture Debt Financing 16
Egalet Raises US$10 Million In Initial Closing Of Venture Financing 17
Egalet Raises US$14.3 Million In Series B2 Financing 18
Egalet Secures Venture Funding 20
Partnerships 21
Egalet Enters into Co-promotion Agreement with Ascend Therapeutics 21
Egalet Enters into Agreement with Teva Pharma 22
Licensing Agreements 23
Egalet Enters into Licensing Agreement with Acura Pharma 23
Equity Offering 24
Egalet to Raise USD8.5 Million in Public Offering of Shares 24
Egalet Plans to Raise upto USD16 Million in Public Offering of Shares 25
Egalet Raises USD30 Million in Public Offering of Shares and Warrants 26
Egalet Raises USD1 Million in Public Offering of Shares 28
Egalet Raises USD0.9 Million in Public Offering of Shares 29
Egalet Raises USD86.3 Million in Public Offering of Shares 30
Egalet Completes IPO For US$58 Million 32
Egalet Completes Private Placement Of Shares For US$15 Million 34
Debt Offering 35
Egalet Raises USD40 Million in Second Tranche of Private Placement of 13% Notes 35
Egalet Raises USD40 Million in First Tranche of Private Placement of 13% Notes 36
Egalet Raises USD60 Million in Private Placement of Notes Due 2020 37
Egalet Corp – Key Competitors 38
Egalet Corp – Key Employees 39
Egalet Corp – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 08, 2018: Egalet reports second quarter 2018 financial results 41
May 08, 2018: Egalet Reports First Quarter 2018 Financial Results 42
Mar 12, 2018: Egalet Reports Fourth Quarter and Full Year 2017 Financial Results 43
Nov 08, 2017: Egalet Announces Third Quarter 2017 Financial Results 44
Aug 09, 2017: Egalet Announces Second Quarter 2017 Financial Results and Expense Reduction Plan 45
May 10, 2017: Egalet Reports First Quarter 2017 Financial Results 46
Mar 09, 2017: Egalet Reports Fourth Quarter and Full Year 2016 Financial Results 48
Corporate Communications 49
Jun 07, 2018: Egalet Names John Varian Board Director 49
Apr 10, 2017: Egalet Announces Changes to Board of Directors 50
Government and Public Interest 51
Nov 20, 2017: Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian Technology 51
Product News 52
05/15/2017: Egalet Announces Scientific Presentations at American Pain Society Meeting 52
Product Approvals 53
Apr 18, 2017: Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage Strengths 53
Clinical Trials 54
Nov 28, 2017: Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain 54
Nov 16, 2017: Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Egalet Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Egalet Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Egalet Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Egalet Corp, Medical Devices Deals, 2012 to YTD 2018 10
Egalet Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Egalet to Acquire Four Non-Narcotic Pain Products from Iroko Pharma 12
Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 14
Egalet Raises USD15 Million in Venture Debt Financing 16
Egalet Raises US$10 Million In Initial Closing Of Venture Financing 17
Egalet Raises US$14.3 Million In Series B2 Financing 18
Egalet Secures Venture Funding 20
Egalet Enters into Co-promotion Agreement with Ascend Therapeutics 21
Egalet Enters into Agreement with Teva Pharma 22
Egalet Enters into Licensing Agreement with Acura Pharma 23
Egalet to Raise USD8.5 Million in Public Offering of Shares 24
Egalet Plans to Raise upto USD16 Million in Public Offering of Shares 25
Egalet Raises USD30 Million in Public Offering of Shares and Warrants 26
Egalet Raises USD1 Million in Public Offering of Shares 28
Egalet Raises USD0.9 Million in Public Offering of Shares 29
Egalet Raises USD86.3 Million in Public Offering of Shares 30
Egalet Completes IPO For US$58 Million 32
Egalet Completes Private Placement Of Shares For US$15 Million 34
Egalet Raises USD40 Million in Second Tranche of Private Placement of 13% Notes 35
Egalet Raises USD40 Million in First Tranche of Private Placement of 13% Notes 36
Egalet Raises USD60 Million in Private Placement of Notes Due 2020 37
Egalet Corp, Key Competitors 38
Egalet Corp, Key Employees 39
Egalet Corp, Other Locations 40
Egalet Corp, Subsidiaries 40

List of Figures
Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Egalet Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Egalet Corp (EGLT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mateon Therapeutics Inc (MATN):企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • Stingray Digital Group Inc.:企業のM&A・事業提携・投資動向
    Stingray Digital Group Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stingray Digital Group Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Asahi Kasei Pharma Corp-製薬・医療分野:企業M&A・提携分析
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • FirstEnergy Corp:企業の発電所・SWOT分析2018
    FirstEnergy Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Renaissance Offshore LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Renaissance Offshore LLC (Renaissance Offshore) is an oil and gas exploration and development company. The company carries out the business of identification and acquisition of under-developed oil and gas assets in the Gulf of Mexico. It builds and manages a portfolio of assets on oil produc …
  • HCA Healthcare Inc (HCA):企業の財務・戦略的SWOT分析
    HCA Healthcare Inc (HCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Ensco Plc (ESV):石油・ガス:M&Aディール及び事業提携情報
    Summary Ensco Plc (Ensco) is a provider of offshore drilling services to the global oil and gas industry. The company owns and operates fleet of drillships, semisubmersibles, moored semisubmersibles, premium jackups and deepwater managed units. It also provides drilling management services to custom …
  • Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報
    Summary Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers medicines for the treatment of cancer, infectious diseases such as HIV, multiple sclerosis and immuno …
  • Ya-Man Ltd:企業の戦略・SWOT・財務分析
    Ya-Man Ltd - Strategy, SWOT and Corporate Finance Report Summary Ya-Man Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • LT Group, Inc. (LTG):企業の財務・戦略的SWOT分析
    LT Group, Inc. (LTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Sumitomo Corporation:企業の戦略・SWOT・財務分析
    Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sunquest Information Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sunquest Information Systems Inc (Sunquest), a subsidiary of Roper Technologies, is a healthcare information technology (IT) company that provides diagnostic informatics solutions to laboratories and healthcare organizations worldwide. The company offers laboratory informatics such as labora …
  • Medicines for Malaria Venture:製薬・医療:M&Aディール及び事業提携情報
    Summary Medicines for Malaria Venture (MMV) is a drug developing company that discovers and delivers new, effective and affordable antimalarial drugs. The center provides products that offers efficacy against drug-resistant strains of plasmodium falciparum, potential for intermittent treatments, saf …
  • Korea Gas Corp (036460):企業の財務・戦略的SWOT分析
    Korea Gas Corp (036460) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Alstom SA (ALO):企業の財務・戦略的SWOT分析
    Alstom SA (ALO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Siemens Medical Solutions USA Inc-医療機器分野:企業M&A・提携分析
    Summary Siemens Medical Solutions USA Inc (Siemens Medical USA), a subsidiary of Siemens Healthcare GmbH is a medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. The company offers products in the areas of medical imagi …
  • Associated Alcohols & Breweries Limited.:企業の戦略・SWOT・財務分析
    Associated Alcohols & Breweries Limited. - Strategy, SWOT and Corporate Finance Report Summary Associated Alcohols & Breweries Limited. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Schiller AG:企業の戦略的SWOT分析
    Schiller AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • LifeAssays AB (LIFE B):医療機器:M&Aディール及び事業提携情報
    Summary LifeAssays AB (LifeAssays) is a medical device company that develops, manufactures and markets in-vitro diagnostic and veterinary care products. The company offers point-of-care diagnostic testing systems. It provides product portfolio such as lifeassays human system and lifeassays veterinar …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆